IMI

Children's Tumor Foundation and Global Coalition for Adaptive Research Announce Strategic Alliance to Implement NF Platform Clinical Trial

Retrieved on: 
Thursday, October 5, 2023

NEW YORK, Oct. 5, 2023 /PRNewswire/ -- The Children's Tumor Foundation (NEW YORK, NY and BRUSSELS, BELGIUM) and the Global Coalition for Adaptive Research (LARKSPUR, CA) – The Children's Tumor Foundation (CTF) and Global Coalition for Adaptive Research (GCAR), today announced their alliance to accelerate the development of treatments for patients with NF (neurofibromatosis or schwannomatosis) – a group of rare and often debilitating diseases with high unmet medical need. CTF and GCAR are partnering to operationalize a first-of-its-kind clinical trial for patients with NF that was initially designed through the EU-PEARL initiative.

Key Points: 
  • CTF and GCAR are partnering to operationalize a first-of-its-kind clinical trial for patients with NF that was initially designed through the EU-PEARL initiative.
  • The establishment of the NF platform trials will expedite the development of effective treatments for patients," said Dr. Annette Bakker, President of the Children's Tumor Foundation.
  • Our alliance with CTF exemplifies a collaboration that places patients and the community at the forefront of clinical research."
  • Additionally, the Foundation's NF Patient Registry provides dependable access to NF patients available to participate in NF clinical trials and research studies.

Tacton Summit 2023 to Examine Simple Sales for Complex Manufacturing

Retrieved on: 
Wednesday, October 4, 2023

CHICAGO and STOCKHOLM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tacton , the leading Configure, Price, Quote (CPQ) SaaS partner to manufacturers for simplifying sales in complex configuration, today announced its plans for Tacton Summit 2023, its annual event taking place on multiple days in October, hosted in Stockholm and Chicago.

Key Points: 
  • CHICAGO and STOCKHOLM, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Tacton , the leading Configure, Price, Quote (CPQ) SaaS partner to manufacturers for simplifying sales in complex configuration, today announced its plans for Tacton Summit 2023, its annual event taking place on multiple days in October, hosted in Stockholm and Chicago.
  • The theme of this year’s summit is “Sales Made Simple for Complex Manufacturing.” The summits will include speakers from Ryder, Valmet, TPC Wire and others discussing their successful CPQ projects and how they’ve revolutionized their operations with Tacton solutions.
  • Tacton Summit Europe will take place Oct. 11-12 in Stockholm with an online option, and Tacton Summit North America will take place Oct. 24-25 virtually.
  • Both Tacton Summit 2023 events will feature:
    Keynotes from industry visionaries: Fresh perspectives from manufacturing pioneers covering emerging trends, challenges, and opportunities shaping the industry.

Norgren to exhibit motion control solutions at PACK EXPO

Retrieved on: 
Monday, August 28, 2023

Norgren , a part of global engineering organization IMI plc, will present its latest pneumatic, electric, and vacuum offerings at PACK EXPO Las Vegas 2023 (September 11 - 13) at the Las Vegas Convention Center.

Key Points: 
  • Norgren , a part of global engineering organization IMI plc, will present its latest pneumatic, electric, and vacuum offerings at PACK EXPO Las Vegas 2023 (September 11 - 13) at the Las Vegas Convention Center.
  • The booth will also feature Norgren’s expanded portfolio of Electric Motion solutions, including Electric Cylinders, Linear Axis, and Multi Axis Systems.
  • "But we are also excited to show PACK EXPO attendees our vast portfolio of options for non-standard applications, for those situations where users must go off-menu.
  • The Norgren booth will have all of our latest automation solutions, but we'll also be there to discuss anybody's design challenges."

Former Pragmatic Institute Executive Rich Nutinsky Joins CI2 Advisors Board of Advisors

Retrieved on: 
Thursday, August 17, 2023

PHILADELPHIA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- CI2 Advisors, LLC , a consulting and behavioral change company, today announced the addition of Rich Nutinsky to its Board of Advisors.

Key Points: 
  • PHILADELPHIA, Aug. 17, 2023 (GLOBE NEWSWIRE) -- CI2 Advisors, LLC , a consulting and behavioral change company, today announced the addition of Rich Nutinsky to its Board of Advisors.
  • Nutinsky has spent 35+ years in enterprise software, product marketing, management and training, including the last 16 years at Pragmatic Institute.
  • Prior to joining Pragmatic, Nutinsky spent 20+ years in enterprise software including stints at Arasys Technologies, IMI and D&B Software.
  • As a CI2 board advisor, Nutinsky is guiding the development of new communication and productivity improvement offerings specifically for product strategy, product management and product management teams.

MSCI Equity Indexes August 2023 Index Review

Retrieved on: 
Thursday, August 10, 2023

MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced the results of the August 2023 Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index, the MSCI China A Onshore indexes and the MSCI China All Shares Indexes.

Key Points: 
  • MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announced the results of the August 2023 Index Review for the MSCI Equity Indexes - including the MSCI Global Standard, MSCI Global Small Cap and MSCI Micro Cap Indexes, the MSCI Frontier Markets, and MSCI Frontier Markets Small Cap Indexes, the MSCI Global Islamic and MSCI Global Islamic Small Cap Indexes, the MSCI US Equity Indexes, the MSCI US REIT Index, the MSCI China A Onshore indexes and the MSCI China All Shares Indexes.
  • MSCI US Equity Indexes: There will be no securities added to and no securities deleted from the MSCI US Large Cap 300 Index.
  • Accordingly, constituents in MSCI equity indexes may include MSCI Inc., clients of MSCI or suppliers to MSCI.
  • MSCI ESG and climate ratings, research and data are produced by MSCI ESG Research LLC, a subsidiary of MSCI Inc. MSCI ESG Indexes, Analytics and Real Estate are products of MSCI Inc. that utilize information from MSCI ESG Research LLC.

Yield10 Bioscience Announces Positive Results in the First Field Test of Stacked Herbicide Tolerance Traits in Camelina, Supporting Large Acreage Production of Low-carbon Intensity Feedstock Oil for the Biofuel Market

Retrieved on: 
Wednesday, August 2, 2023

WOBURN, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced positive results in the first field test of stacked herbicide tolerance (“HT”) traits in Camelina. These proprietary stacked HT Camelina varieties developed by Yield10 demonstrate tolerance to the application of an over-the-top herbicide for weed control as well as tolerance to Group 2 herbicide soil residues. These results represent a key advancement for supporting grower adoption of stacked HT Camelina for the biofuel feedstock market by enabling weed control and increased access to acreage previously treated with Group 2 herbicides. Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide traits to achieve large acreage adoption of the crop in North America.

Key Points: 
  • WOBURN, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced positive results in the first field test of stacked herbicide tolerance (“HT”) traits in Camelina.
  • These proprietary stacked HT Camelina varieties developed by Yield10 demonstrate tolerance to the application of an over-the-top herbicide for weed control as well as tolerance to Group 2 herbicide soil residues.
  • These results represent a key advancement for supporting grower adoption of stacked HT Camelina for the biofuel feedstock market by enabling weed control and increased access to acreage previously treated with Group 2 herbicides.
  • Yield10 is executing a program to develop and commercialize spring and winter Camelina varieties with stacked herbicide traits to achieve large acreage adoption of the crop in North America.

International Materials Appoints Robert K. Walsh as Chief Executive Officer

Retrieved on: 
Thursday, July 27, 2023

International Materials LLC (IMI), today announced that its Board of Directors has appointed Robert K. Walsh as Chief Executive Officer, effective immediately.

Key Points: 
  • International Materials LLC (IMI), today announced that its Board of Directors has appointed Robert K. Walsh as Chief Executive Officer, effective immediately.
  • In addition to assuming the role of CEO, Mr. Walsh will continue to fulfill his responsibilities as President as IMI moves forward into the next phase of its growth and expansion.
  • View the full release here: https://www.businesswire.com/news/home/20230727884788/en/
    Mr. Walsh joined IMI as a trader trainee in July 1994 after graduating from Villanova University in Pennsylvania.
  • "Throughout his career, Rob has been a true embodiment of our company's core values: entrepreneurship, innovation, and personal accountability.

C-Path Integrates European Offices to Optimize Global Operations and Collaborative Partnerships

Retrieved on: 
Tuesday, July 18, 2023

This integration will enable C-Path to increase its activity in Europe and broaden its global operations.

Key Points: 
  • This integration will enable C-Path to increase its activity in Europe and broaden its global operations.
  • "We are thrilled to bring the talented European teams together as a unified organisation.
  • Doing so allows us to expand our presence in Europe and strengthen our global operations.
  • With this strengthened global presence, it remains committed to leading collaborations that accelerate drug development, advancing better treatments for people worldwide.

SUPCON Gains Momentum in Saudi Arabia and the Gulf with Recent Project Wins

Retrieved on: 
Tuesday, July 4, 2023

HANGZHOU, China, July 4, 2023 /PRNewswire/ -- SUPCON (688777.SH, SUPCON.SW), a trailblazer in process automation and digital transformation in China, has announced a series of project wins across Saudi Arabia and the Gulf.

Key Points: 
  • HANGZHOU, China, July 4, 2023 /PRNewswire/ -- SUPCON (688777.SH, SUPCON.SW), a trailblazer in process automation and digital transformation in China, has announced a series of project wins across Saudi Arabia and the Gulf.
  • These recent project wins demonstrate SUPCON's capability to provide a wide range of solutions from instrumentation, automation & information to top-level management solution.
  • The company has been expanding into the Gulf region with ambitious planning and preparation, leveraging the increasingly strong economic ties between China and Saudi Arabia, especially under the backdrop of Belt & Road Initiative and Vision 2023.
  • These visits herald a new era of SUPCON's partnership with major players in Saudi Arabia and the Gulf.

The HARMONY Alliance is set to become a research foundation

Retrieved on: 
Wednesday, June 7, 2023

The HARMONY Alliance has revolutionized the use of big data in Hematologic Malignancies research.

Key Points: 
  • The HARMONY Alliance has revolutionized the use of big data in Hematologic Malignancies research.
  • THE HAGUE, Netherlands, June 7, 2023 /PRNewswire/ -- The HARMONY Alliance has revolutionized the use of big data to accelerate developments in treating patients with Hematological Malignancies.
  • The Alliance is made up of HARMONY and HARMONY PLUS – both funded by the European Commission's Innovative Health Initiative (IHI), formerly known as IMI.
  • Patients will be given a clear voice in the foundation and the patient-centered approach will remain paramount in all our research activities.